ResearchMoz

Global and China Monoclonal Antibody Industry Report, 2013 - 2017

Research In China
Published Date » 2013-12-23
No. Of Pages » 118
 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017. 
   
 Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is...
Table of Content

1 Overview of Monoclonal Antibody Industry
1.1 Definition
1.2 Classification
1.3 Technological Development

2 Overview of Global Monoclonal Antibody Industry 
2.1 Status Quo 
2.2 Market Size 
2.3 Competition Pattern 
2.4 Development Prospect and Prediction
2.4.1 Market Size 
2.4.2 Competition Pattern 
2.4.3 R & D Trend 

3 Chinese Monoclonal Antibody Market 
3.1 Status Quo 
3.2 Market Size 
3.3 Market Segments
3.3.1 Rituximab/Rituxan
3.3.2 Trastuzumab/Herceptin
3.3.3 Cetuximab/Erbitux
3.3.4 Nimotuzumab/Infilixmab
3.3.5 Bevacizumab
3.3.6 Recombinant Human Tumor Necrosis Factor Receptor Type II - Antibody Fusion Protein
3.4 Competition Pattern 
3.5 Development Prospect 

4 Key Foreign Monoclonal Antibody Agent Enterprises
4.1 Roche Pharmaceuticals
4.1.1 Profile
4.1.2 Operation 
4.1.3 Revenue Structure 
4.1.4 R & D and Investment
4.1.5 Monoclonal Antibody Business (Genentech) 
4.1.6 Business in China 
4.2 Johnson & Johnson 
4.2.1 Profile
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 R & D and Investment
4.2.5 Monoclonal Antibody Business 
4.2.6 Business in China 
4.3 Merck 
4.3.1 Profile
4.3.2 Operation 
4.3.3 Revenue Structure 
4.3.4 R & D and Investment
4.3.5 Monoclonal Antibody Business 
4.3.6 Business in China 
4.4 NVS 
4.4.1 Profile
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 R & D and Investment
4.4.5 Monoclonal Antibody Business 
4.4.6 Business in China 
4.5 AbbVie
4.5.1 Profile
4.5.2 Revenue Structure 
4.5.3 R & D and Investment 
4.5.4 Monoclonal Antibody Business 
4.5.5 Business in China 
4.6 Amgen 
4.6.1 Profile
4.6.2 Operation 
4.6.3 Revenue Structure 
4.6.4 R & D and Investment
4.6.5 Monoclonal Antibody Business 
4.6.6 Business in China 

5 Key Chinese Monoclonal Antibody Agent Enterprises
5.1 Shanghai Lansheng States Kin Pharmaceutical Co., Ltd. 
5.1.1 Profile
5.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd.
5.1.3 Shanghai Zhangjiang Biotech Co., Ltd. 
5.1.4 Shanghai CP GuoJian Biotech Academy
5.1.5 Shanghai Guosheng Pharmaceutical Co., Ltd. 
5.2 Beijing Biotech Pharmaceutical Co., Ltd.
5.2.1 Profile
5.2.2 Competitive Edges
5.2.3 Development Prospect 
5.3 Chengdu Huasun Group Co., Ltd.
5.3.1 Profile
5.3.2 Chengdu Huasun Biotech Co., Ltd.
5.4 Shanghai Medipharm Biotech Co., Ltd.
5.4.1 Profile
5.4.2 Monoclonal Antibody Business 
5.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.5.1 Profile
5.5.2 Monoclonal Antibody Business 
5.6 Yunnan Walvax Biotechnology Co., Ltd.
5.6.1 Profile
5.6.2 Monoclonal Antibody Business 
5.7 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.7.1 Profile
5.7.2 Monoclonal Antibody Business 
5.8 Beijing SL Pharmaceutical Co., Ltd.
5.8.1 Profile
5.8.2 Monoclonal Antibody Business 
5.9 Shenzhen Main Luck Pharmaceuticals Inc.
5.9.1 Profile
5.9.2 Monoclonal Antibody Business 
5.10 Huahai Pharmaceutical Co., Ltd.
5.10.1 Profile
5.10.2 Monoclonal Antibody Business 

6 Summary and Forecast
6.1 Comparison between Domestic and Foreign Companies
6.2 Market Forecast

List of Tables


List of Figures

Upcoming Reports:

IV Therapy and Vein Access Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The global market for intravenous and vein access devices encompasses a variety of devices such as peripheral venous access, central venous access, ambulatory infusion, enteral feeding, syringe infusion, implantable pumps and diabetes insulin infusion devices. These devices are used for intravenous administration of drugs, fluid infusion, blood sampling, venous pressure monitoring, blood and transfusion. Implantable ports, catheters, syringes, needles and needless connectors are examples of various intravenous therapy and vein access devices. Some of the commercially available...
Treatments For Neurodegenerative Disorders - Global Forecast, Market Share, Size, Growth And Industry Analysis, 2012 - 2018
By - Transparency Market Research
Neurodegenerative disorders cause progressive loss of function structure of the neurons in the human brain. The most commonly known neurodegenerative diseases are Alzheimer’s, Parkinson’s, Amyotrophic lateral sclerosis, and Huntington’s Syndrome. Most neurodegenerative disorders are caused because of genetic mutation in completely unrelated cells. Increase in the awareness regarding mental disorders and the rise in research and development regarding the treatment of such disorders are the major factors that are driving the growth of this market. However, despite...
Bunker Oil Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The shipping industry is facing challenges due to strong regulations against the use of bunker oil for large ships. Bunker oil is a waste product of traditional fuel oil that is too thick for vehicles and small ships to burn efficiently. Its high sulfur content and difficulty for use in road vehicles makes it a cheaper power source for large ships and power plants. Bunker fuel degrades slower than standard fuel oil and produces a mixture of sulfur dioxide, carbon dioxide, and other pollutants when burned. Due to these ill-effects, bunker fuel oil is replaced by gasoil for a...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...
Sony plans revival of PlayStation with network services
Jul 29, 2014  
After a nearly USD 10 billion loss over the last six years, Sony Corp has plans of reviving its consumer electronics hero – the PlayStation. Sony will be repositioning the video game console as a center of streamed network services such as social media, music and movies apart from games. The matter is still in its infancy stage of discussion and the plan is to generate revenue from the...